

PATENT
2815-0187P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: TEUBER, Lene et al. Conf.:
Appl. No.: New Group:
Filed: December 28, 2001 Examiner:
For: POTASSIUM CHANNEL BLOCKING AGENTS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

December 28, 2001

Sir:

The following preliminary amendments and remarks are respectfully submitted in connection with the above-identified application.

TEUBER - 2815-0187P

IN THE CLAIMS:

Please amend the claims as follows:

13. (Amended) A chemical compound according to claim 1, for use as a medicament.

14. (Amended) The use of a chemical compound according to claim 1 for the manufacture of a medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is associated with the activity of potassium channels.

16. (Amended) A pharmaceutical composition comprising a therapeutically-effective amount of a chemical compound according to claim 1, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

17. (Amended) A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to blockade of the potassium channel, and which method comprises administering to such a living animal body, including a human, in need thereof a therapeutically-effective amount of a compound of claim 1.

REMARKS

The claims have been amended to delete multiple dependencies.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the application by this Amendment.


Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Gerald M. Murphy, Jr., (Reg. #28,977) at the telephone number of the undersigned below.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By



Gerald M. Murphy, Jr., #28,977

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

GMM/rem
2815-0187P
Attachments

(Rev. 12/19/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

The claims have been amended as follows:

13. (Amended) A chemical compound according to [any of claims 1-12] claim 1, for use as a medicament.

14. (Amended) The use of a chemical compound according to [any of claims 1-12] claim 1 for the manufacture of a medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is associated with the activity of potassium channels.

16. (Amended) A pharmaceutical composition comprising a therapeutically-effective amount of a chemical compound according to [any of claims 1-12] claim 1, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

17. (Amended) A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to blockade of the potassium channel, and which method comprises administering to such a living animal body, including a human, in need thereof a therapeutically-effective amount of a compound of [any of claims 1-12] claim 1.